Physician profile
Shereen J Chang
NPI 1508917857
$2,046.37
in general payments reported to CMS, 2019-2025
30 companies · $543 in 2025
The $543 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $429 · 2020: $480 · 2021: $123 · 2022: $50.38 · 2023: $135 · 2024: $286 · 2025: $543.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $964.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $963.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $522.20 | 2024-2025 | |
| Allergan, INC. | $432.08 | 2019-2021 | |
| Abbvie INC. | $203.59 | 2019-2025 | |
| Biogen, INC. | $79.89 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $78.04 | 2023-2025 | Dysport |
| Abbott Laboratories | $69.10 | 2023-2024 | Jot Dx, Infinity |
| Amgen INC. | $67.49 | 2019-2024 | Uplizna |
| Lilly USA, LLC | $59.23 | 2019-2024 | Kisunla, Amyvid |
| Janssen Pharmaceuticals, INC | $53.40 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $39.54 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.72 | 2023-2025 | Hyqvia, Gammagard |
| Genentech USA, INC. | $37.51 | 2019-2021 | |
| Lundbeck LLC | $35.66 | 2020-2024 | Vyepti |
| Ucb, INC. | $28.09 | 2019 | |
| Greenwich Biosciences, INC. | $24.49 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $23.59 | 2020 | |
| Sunovion Pharmaceuticals INC. | $23.04 | 2020 | |
| Ge Healthcare | $21.61 | 2019 | |
| Resmed Corp | $21.33 | 2019 | |
| Supernus Pharmaceuticals, INC. | $21.14 | 2019 | |
| Argenx US, INC. | $20.82 | 2025 | Vyvgart Hytrulo, Vyvgart |
| Tg Therapeutics, INC. | $20.28 | 2023 | |
| Jazz Pharmaceuticals INC. | $19.19 | 2019 | |
| Acorda Therapeutics, INC | $19.16 | 2019 | |
| Novartis Pharmaceuticals Corporation | $18.17 | 2019 | |
| Tanabe Pharma America, INC. | $16.34 | 2019 | |
| Celgene Corporation | $14.73 | 2021 | |
| Axsome Therapeutics, INC. | $14.61 | 2025 | Sunosi |
| Biohaven Pharmaceutical Holding Company LTD. | $12.49 | 2022 | |
| Livanova USA, INC. | $10.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shereen Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.